A Phase III, Randomised, Double-blind, Placebo-controlled, Parallel-group Study to Assess the Effect of AZD0780 on Major Adverse Cardiovascular Events in Patients With Established Atherosclerotic Cardiovascular Disease (ASCVD) or at High Risk for a First ASCVD Event
Latest Information Update: 06 Jun 2025
At a glance
- Drugs AZD 0780 (Primary)
- Indications Acute coronary syndromes; Atherosclerosis; Cardiovascular disorders; Ischaemia; Ischaemic stroke; Myocardial infarction
- Focus Adverse reactions; Registrational
- Acronyms AZURE-Outcomes
- Sponsors AstraZeneca
Most Recent Events
- 06 Jun 2025 New trial record